Linker Information
General Information of This Linker
| Linker ID |
LIN0QGXDL
|
|||||
|---|---|---|---|---|---|---|
| Name |
Maleimide linker of vc PAB
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
JS107 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility criteria: Patients aged 18-75 with histologically confirmed locally advanced/metastatic solid tumors, ECOG 0-1, measurable lesions, and adequate organ function. Major exclusions: prior CLDN18.2-targeted therapy, severe allergies to JS107 components, recent anticancer treatments (within 4 weeks), uncontrolled infections (HBV/HCV/HIV), symptomatic CNS metastases, or significant cardiopulmonary comorbidities.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05657418 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Pancreatic Cancer
|
||||
| Primary Endpoint |
Primary endpoints focus on determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for JS107 monotherapy and combination therapy, with evaluation timelines up to 12 and 24 months respectively from first patient enrollment.
|
||||
| Other Endpoint |
Secondary objectives include pharmacokinetic analysis of drug plasma concentrations, immunogenicity assessment (ADA/Nab incidence and titers), and efficacy evaluation through objective response rate (ORR) per RECIST v1.1 criteria, all monitored over 24 months.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Key eligibility: Adults (18-75) with histologically confirmed advanced/metastatic solid tumors (ECOG 0-1, measurable lesions). Major exclusions: prior CLDN18.2 therapy, severe allergies to JS107 components, recent anticancer treatments (4 weeks), active infections (HBV/HCV/HIV/TB), uncontrolled CNS metastases, significant cardiopulmonary disease, or autoimmune disorders.
Click to Show/Hide
|
||||
| Administration Dosage |
JS107, i.v., q3w
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05502393 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include MTD determination (12 months) and RP2D establishment (24 months) for JS107 monotherapy/combination therapy in advanced solid tumor patients.
|
||||
| Other Endpoint |
Secondary objectives cover PK analysis (drug concentrations), immunogenicity (ADA/Nab incidence/titers), and efficacy (ORR per RECIST v1.1), all monitored over 24 months.
|
||||
References